ROBBINSVILLE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NexMed, Inc. , a developer of innovative treatments based on the NexACT(R) drug delivery technology, today announced that Dr. Marc Gittelman, MD, FACS, Director of the Miami Center for Sexual Health and a NexMed consultant, will make two Femprox presentations at the Annual Meeting of the International Society for the Study of Women’s Sexual Health (“ISSWSH”), which takes place October 27-30, 2005 in Las Vegas, NV. Femprox(R) is NexMed’s proprietary FSAD treatment under development and incorporates alprostadil (PGE1) with the patented NexACT(R) technology.
-- Poster P58 - Friday, October 28, 2005 from 2:00 PM to 4:00 PM Effects of a Specially Formulated Topical Alprostadil Cream by a Continuous Dosing Schedule for the Treatment of Female Sexual Arousal Disorder. -- Podium Presentation - Saturday, October 29, 2005 4:18 PM A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of an Alprostadil Topical Cream in Patients with Female Sexual Arousal Disorder.
Dr. Gittelman commented, “I am pleased to share our clinical results with a prestigious group of clinicians who specialize in the research, education and clinical practice of women’s sexuality. We look forward to further clinical development of this product.”
In addition to a completed U.S. Phase 2 study, NexMed recently announced that it has completed testing for its 400-patient study for Femprox(R) in China. The primary and secondary efficacy endpoint was statistically significant at the end of both evaluation periods. Improved sexual satisfaction among FSAD patients was observed in an ascending dose ranging trend. The study is double-blind, placebo-controlled and randomized, and designed to test the efficacy and safety of Femprox(R) cream in women diagnosed with female sexual arousal disorder. The side effects reported were mostly mild or moderate in intensity, reversible and short in duration. NexMed is actively seeking potential pharmaceutical partners to co-develop Femprox.
Conference Call
NexMed management will host a conference call on Wednesday, November 9, 2005 at 10:30AM ET, to discuss third quarter 2005 results and to provide an update on its product pipeline. The Company intends to file its Form 10-Q for the quarter ended September 30, 2005 on the same day. The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054, and asking the conference operator for the NexMed Conference Call. Playback is available until November 16, 2005, both account# 286 and ID# 175520 are required for access. The conference call will also be Web cast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=97168.
About NexMed, Inc.
NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to enter into partnering agreements or raise financing on acceptable terms, successful completion of clinical development programs, regulatory review and approval, product development and acceptance, manufacturing, competition, and/or other factors, some of which are outside the control of the Company.
NexMed, Inc.
CONTACT: Deborah Carty of NexMed, Inc., +1-609-208-9688, ext. 159,dcarty@nexmed.com, or Media: Marni Kotak of Excite Media Group,+1-212-941-8499 x102, mkotak@excitepr.com, for NexMed
Web site: http://www.nexmed.com/
